Moderna raises its revenue outlook — but all eyes are on what happens next with its experimental cancer vaccine
The company lifted its revenue outlook for the year, saying it expects revenue to grow as much as 25% in 2026.
VolFlash analysisNot analysed
This event fell outside the real-time analysis window (published more than 6 hours ago), so no analysis was generated. Live events are analysed within a minute of publication.
Related guidesHow markets transmit
One email a day — don't miss the big ones
The 8 highest-severity events of the past 24h, with our read and source links. Unsubscribe anytime.
Published：2026-11-06 14:14:09 · Source：marketwatch · Automatically aggregated and analysed — verify against the original source.